Glooko Launches Glooko EndoTool IV Cloud, Advancing Patient-Specific Glycemic Management for Hospitals

Glooko Launches Glooko EndoTool IV Cloud, Advancing Patient-Specific Glycemic Management for Hospitals

FDA-cleared solution combines EndoTool's established clinical intelligence with a streamlined clinician experience and modern SaaS architecture built for enterprise scale

Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced the commercial launch of Glooko EndoTool IV Cloud, its FDA 510(k)-cleared, SaaS-based inpatient IV insulin dosing solution. Glooko EndoTool IV Cloud combines EndoTool's established patient-specific clinical intelligence with a modern clinical experience and cloud architecture designed to simplify deployment, reduce technical complexity, and support health-system scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102401555/en/

Glooko EndoTool IV Cloud

Inpatient glycemic management remains a system-level challenge. Clinicians must respond to changing patient conditions while managing the risk of both hypoglycemia and hyperglycemia, often within high-acuity, demanding workflows. Patient complexity can make glycemic control less predictable, while variability across protocols, handoffs, and clinical interpretation can create additional burden for care teams and health systems. The launch also comes as severe hypoglycemia and severe hyperglycemia are increasingly visible as hospital quality priorities, including through CMS Hospital Harm electronic clinical quality measures (eCQMs).

"Health systems today need technology that helps clinicians manage complex care more consistently and can be deployed and supported without adding unnecessary friction," said Mike Alvarez, Chief Executive Officer of Glooko. "Glooko EndoTool IV Cloud brings together EndoTool's patient-specific clinical intelligence with a modern SaaS experience designed for the needs of today's hospital clinical and technical teams. It is an important step in our mission to simplify diabetes and glycemic care and help customers scale trusted clinical value across the enterprise."

Glooko EndoTool IV Cloud calculates a patient-specific insulin dosing model using available patient demographics and laboratory values and continually updates that model based on factors such as current glucose trends, kidney function, and changes in insulin sensitivity over time. Glooko EndoTool IV Cloud brings that approach into a purpose-built SaaS product with a redesigned clinical experience. Key elements include:

• Patient-specific IV insulin dosing recommendations based on the established, evidence-supported EndoTool algorithm and continually updated patient response.
• A streamlined user experience with minimal screens and clicks, consolidated access to key dosing information, and workflow design intended to reduce cognitive disruption at the bedside.
• Modern SaaS delivery designed to eliminate the on-premises technology footprint, simplify deployment and ongoing management, and support scaling across health systems.
• Built to meet hospital security expectations, with SOC 2 Type II certification and safeguards designed to protect patient information and support HIPAA compliance.

The foundational EndoTool clinical decision support algorithm has an established clinical track record of helping hospitals improve glycemic management, including reducing hypoglycemia, achieving target glucose levels faster, and reducing the number of glucose checks required. In 2025 EndoTool IV customer outcomes data, the average severe hypoglycemia rate below 40 mg/dL was 0.006% across EndoTool IV customers.*

"Managing IV insulin safely means responding to how an individual patient changes over time, not simply applying the same static protocol to everyone," said Paul Chidester, M.D., Medical Director, EndoTool at Glooko. "EndoTool is designed to continuously adapt its dosing model to each patient's response. With Glooko EndoTool IV, we are preserving that clinical logic, safety guardrails, and decision-support approach while giving clinicians a more streamlined experience that makes key information easier to access at the bedside."

Glooko EndoTool IV is now commercially available in the United States.

About Glooko EndoTool IV Cloud

Glooko EndoTool IV Cloud is a clinical decision support solution designed to support patient-specific intravenous (IV) insulin dosing in the hospital setting. The algorithm uses available patient-specific data to recommend insulin dosing adjustments and support clinicians to safely manage glycemic control for patients requiring IV insulin therapy. Glooko EndoTool IV Cloud brings this capability into a modern SaaS environment with a streamlined clinical experience and cloud-based deployment model. The platform is built to meet hospital security expectations, with SOC 2 Type II certification and safeguards designed to protect patient information and support HIPAA compliance.

About Glooko

Glooko, Inc. is a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum. Across inpatient and outpatient settings, Glooko combines clinical expertise, software, and connected data capabilities to help health systems simplify workflows, support more consistent care, and strengthen connections between care teams and the people they serve.

EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Recommendations are intended to assist, and not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.

*Source: 2025 EndoTool IV customer outcome data available on file.

Media Contact
Julia Fuller
Vice President, Corporate Communications & Brand
pr@glooko.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20261102401555/en/